Published in BMC Cancer on June 19, 2010
The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications. ScientificWorldJournal (2011) 0.91
The role of Hypoxia-inducible factor-1 α , glucose transporter-1, (GLUT-1) and carbon anhydrase IX in endometrial cancer patients. Biomed Res Int (2014) 0.87
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Front Oncol (2016) 0.85
Expression of hypoxic markers and their prognostic significance in soft tissue sarcoma. Oncol Lett (2015) 0.83
SHARP1 suppresses angiogenesis of endometrial cancer by decreasing hypoxia-inducible factor-1α level. PLoS One (2014) 0.82
Clinicopathological characteristics of gynecological cancer associated with hypoxia-inducible factor 1α expression: a meta-analysis including 6,612 subjects. PLoS One (2015) 0.81
Expression and significance of MMP2 and HIF-1α in hepatocellular carcinoma. Oncol Lett (2014) 0.81
Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway. Oncotarget (2016) 0.81
Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. Oncotarget (2015) 0.78
Incomplete radiofrequency ablation accelerates proliferation and angiogenesis of residual lung carcinomas via HSP70/HIF-1α. Oncol Rep (2016) 0.77
Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. Oncotarget (2016) 0.77
The recent progress of the mechanism and regulation of tumor necrosis in colorectal cancer. J Cancer Res Clin Oncol (2015) 0.77
Carbogen gas and radiotherapy outcomes in prostate cancer. Ther Adv Urol (2013) 0.75
HIF-1α and GLUT-1 Expression in Atypical Endometrial Hyperplasia, Type I and II Endometrial Carcinoma: A Potential Role in Pathogenesis. J Clin Diagn Res (2016) 0.75
The role of hypoxic-inducible factor (HIF1α) and aldolaseC protein in endometrial carcinogenesis: a retrospective study of 279 patients. BMJ Open (2012) 0.75
Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. J Gynecol Oncol (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol (1999) 9.32
HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol (1985) (2000) 5.75
Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol (1996) 5.52
Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem (1996) 5.15
The Pezcoller lecture: cancer cell cycles revisited. Cancer Res (2000) 5.08
No consent should be needed for using leftover body material for scientific purposes. For. BMJ (2002) 3.77
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med (1997) 3.57
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res (2000) 3.35
Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 3.25
Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol (2005) 2.70
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res (2002) 2.57
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene (2003) 2.22
Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer (2001) 2.11
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol (2005) 2.10
Hypoxic gene expression and metastasis. Cancer Metastasis Rev (2004) 2.01
Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist (2004) 1.88
Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res (1996) 1.84
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res (2002) 1.84
Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol (1998) 1.78
A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol (2000) 1.51
Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer (2002) 1.27
Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer (2003) 1.24
Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. Cancer J Sci Am (1998) 1.16
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res (1999) 1.10
Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer (2004) 1.09
Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol (2005) 1.08
Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia (2001) 1.06
Hypoxia and angiogenesis in endometrioid endometrial carcinogenesis. Cell Oncol (2007) 1.00
Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer (2004) 0.97
Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer (2006) 0.96
Stimulation of Glucose Transport by Hypoxia: Signals and Mechanisms. News Physiol Sci (1999) 0.96
Role of bicarbonate in the regulation of intracellular pH in the mammalian ventricular myocyte. Biochem Cell Biol (2002) 0.90
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas. Clin Cancer Res (2003) 0.89
Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Mod Pathol (2006) 0.89
Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters. Br J Cancer (2002) 0.87
Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecol Oncol (2002) 0.85
Hypoxia-inducible factor 1 alpha is essential for hypoxic p27 induction in endometrioid endometrial carcinoma. J Pathol (2008) 0.85
The role of p27 in endometrial carcinoma. Gynecol Oncol (2001) 0.84
Hypoxia contributes to development of recurrent endometrial carcinoma. Int J Gynecol Cancer (2007) 0.84
Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia. Virchows Arch (1999) 0.82
p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. Gynecol Oncol (2000) 0.80
The reproducibility of a binary tumor grading system for uterine endometrial endometrioid carcinoma, compared with FIGO system and nuclear grading. Oncology (2004) 0.80
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med (2009) 5.36
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev (2009) 3.25
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol (2002) 2.56
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol (2005) 2.42
Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol (2013) 2.19
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest (2002) 2.06
Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer (2002) 1.98
Brief fixation does not affect assessment of hormone receptor expression in invasive breast carcinoma biopsies: paving the road for same-day tissue diagnostics. Am J Surg Pathol (2014) 1.95
Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (2004) 1.92
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem (2009) 1.83
Alternatives for randomization in lifestyle intervention studies in cancer patients were not better than conventional randomization. J Clin Epidemiol (2012) 1.71
HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell Oncol (2009) 1.70
Going fully digital: Perspective of a Dutch academic pathology lab. J Pathol Inform (2013) 1.67
Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res (2011) 1.64
HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol (2006) 1.59
Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol (2007) 1.58
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer (2010) 1.57
The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy. Eur J Nucl Med Mol Imaging (2004) 1.56
Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review. Breast Cancer Res Treat (2010) 1.53
Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene (2003) 1.52
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer (2011) 1.52
Creation of a fully digital pathology slide archive by high-volume tissue slide scanning. Hum Pathol (2010) 1.52
Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology (2009) 1.51
The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol (2005) 1.49
Breast cancer histopathology image analysis: a review. IEEE Trans Biomed Eng (2014) 1.47
TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst (2004) 1.45
Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma. Gynecol Oncol (2004) 1.45
Sentinel node biopsy for nonpalpable breast tumors requires a preoperative diagnosis of invasive breast cancer. Breast J (2003) 1.44
Comparing bivalent and quadrivalent HPV vaccines. BMJ (2011) 1.43
Automatic nuclei segmentation in H&E stained breast cancer histopathology images. PLoS One (2013) 1.43
Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med (2008) 1.41
The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol (2006) 1.41
Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers. Endocr Relat Cancer (2012) 1.40
The 3-layered ductal epithelium in gynecomastia. Am J Surg Pathol (2012) 1.40
Confocal 3D DNA cytometry: assessment of required coefficient of variation by computer simulation. Cell Oncol (2004) 1.39
The Value of Endocervical Curettage in Addition to Biopsies in Women Referred to Colposcopy. J Low Genit Tract Dis (2015) 1.39
Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology (2005) 1.37
Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer (2007) 1.37
Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol (2011) 1.34
Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer (2011) 1.34
Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging (2012) 1.33
Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol (2004) 1.33
Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol (2011) 1.32
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol (2003) 1.31
c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol (2006) 1.30
COMMD1 disrupts HIF-1alpha/beta dimerization and inhibits human tumor cell invasion. J Clin Invest (2010) 1.28
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer (2007) 1.27
Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon. Ann Surg (2009) 1.24
Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.22
Whole slide images for primary diagnostics in dermatopathology: a feasibility study. J Clin Pathol (2011) 1.21
Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J Pathol (2003) 1.21
Whole slide images for primary diagnostics of gastrointestinal tract pathology: a feasibility study. Hum Pathol (2011) 1.21
Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene (2003) 1.20
Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer (2006) 1.20
The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol (2010) 1.19
Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer (2012) 1.18
Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol (2011) 1.17
High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat (2007) 1.16
Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol (2010) 1.16
Do we see what we think we see? The complexities of morphological assessment. J Pathol (2009) 1.16
Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J Pathol (2003) 1.13
Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest (2011) 1.13
Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat (2009) 1.13